Multi-institutional retrospective observational study of effectiveness and safety of treatment with Nivolmab for advanced or recurrent non-small cell lung cancer harboring EGFR mutation.

Multi-institutional retrospective observational study of effectiveness and safety of treatment with Nivolmab for advanced or recurrent non-small cell lung cancer harboring EGFR mutation. - Multi-institutional retrospective observational study of effectiveness and safety of treatment with Nivolmab for advanced or recurrent non-small cell lung cancer harboring EGFR mutation.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025261

Enrollment

100

Registered

2016-12-31

Start date

2016-12-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NSCLC patients harboring EGFR gene mutation, who were treated with Nivolmab by the end of December 2016, are eligible for this study.

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
effectiveness and safety	—

Secondary

Measure	Time frame
Response rate Progression free survival Overall survival Adverse events	—

Countries

Japan

Contacts

Public ContactYuki Akazawa

Toneyama National Hospital Department of Thoracic Oncology

akazaway@toneyama.go.jp06-6853-2001

Outcome results